Bharat Book

PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022

Press Release   •   Dec 09, 2013 11:24 IST

Dec 9, 2013 : Bharat Book Bureau presents the new report, on ''PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022" this report gives Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.


Summary
“PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022”. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer’s Dilantin, Abbott’s Depakote, and Novartis’ Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline’s Trobalt/Potiga and Eisai’s Fycompa which both offer first-in-class mechanisms of action.

Due to China’s vast general population, which drives the growth of the prevalent population of epilepsy patients, the AED market is fairly large, despite the relatively low cost of treatment. The main driver for growth in this market will be the continued uptake of recent AEDs, a growing middle class with better healthcare access, and increased epilepsy treatment in the whole population due to government efforts to increase healthcare access. However, loose government regulation of patent protection, as well as a reliance on traditional Eastern medicine, severely impact brand drug penetration and profitability in China.

Scope

- Overview of Epilepsy including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Epilepsy market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China

Table of Contents: 
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Classification of Seizures 15
3.2 Etiology and Pathophysiology 16
3.2.1 Etiology 16
3.2.2 Pathophysiology 19
3.2.3 Prognosis 24
3.2.4 Quality of Life 25
4 Disease Management 26
4.1 Diagnosis 26
4.2 Treatment Guidelines 27
4.3 Clinical Practice 28
4.4 China 34
4.4.1 Diagnosis 34
4.4.2 Clinical Practice 35
5 Competitive Assessment 37
5.1 Overview 37
5.2 Strategic Competitor Assessment 38
5.3 Product Profiles – Major Brands 41
5.3.1 Keppra (levetiracetam) 41
5.3.2 Lamictal (lamotrigine) 45
5.3.3 Lyrica (pregabalin) 49
5.3.4 Zonegran (zonisamide) 52
5.3.5 Older-Generation AEDs 55
6 Opportunity and Unmet Need 56

For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/pharmapoint-epilepsy-china-drug-forecast-and-market-analysis-to-2022.html

Related link : www.bharatbook.com/market-research-report/pharmaceuticals-and-healthcare.html

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Email: info@bharatbook.com 
Website: www.bharatbook.com 
Follow us on twitter: https://twitter.com/researchbook 
Follow us on linked in : http://www.linkedin.com/company/bharat-book-bureau 
Our Blog : http://blog.bharatbook.com/ 


Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.